Product Overview
Dragon Pharma HMG 150 IU is a single vial of lyophilised menotropin, the gonadotropin prepared from the urine of postmenopausal women and sold clinically under names such as Repronex. The material is a biologically standardised glycoprotein rather than a pure peptide, so it is measured in international units and not in milligrams, and the classic reference split is 75 IU of follicle stimulating hormone activity together with 75 IU of luteinising hormone activity per vial. The catalogue entry here is the 150 IU format, and the powder is dissolved with bacteriostatic water before use.
The two hormone activities explain where the product belongs. The FSH fraction speaks to the Sertoli cells inside the seminiferous tubules and is the part connected to sperm production; the LH fraction speaks to the Leydig cells, the same cells that human chorionic gonadotropin already targets. That division of labour is why a recovery plan built around HCG 5000 iu may add this vial instead of replacing it, since only the FSH side reaches spermatogenesis. Clinical labelling describes daily injections over roughly ten days for ovulation induction, while male use in the literature is cast as stimulation of sperm production in hypogonadism.
Three facts should be stated plainly, because each one is a place where invented numbers tend to appear. The elimination half-life is not confirmed in the sources consulted for this card, and no figure is quoted. The exact detection window is likewise unconfirmed, although immunoassay can identify the hormone in a sample. And the substance is prohibited for male athletes at all times under WADA class S2.2.1. For the estradiol side of a combined protocol the Aromasin page is the natural companion read.
Dosage Protocol
Amounts are quoted in international units, following the clinical references collected for this card and the vendor practice attached to the 150 IU pack. They are recorded as reference data, not as a prescription.
| Starting level | 75 IU a day for 5-10 days; the small volume makes an insulin-style barrel the practical choice |
| Middle level | 75-150 IU a day over 10-14 days, usually alongside hCG so Leydig and Sertoli support run together |
| Upper level | 150 IU a day and above, close to clinical fertility schemes, and only with laboratory monitoring |
| Female | No bodybuilding protocol exists in the sources; the clinical use in women is ovulation induction, conducted under medical supervision |
| Route | Subcutaneous or intramuscular; the lyophilised powder is dissolved in bacteriostatic water and clinical schedules call for daily dosing over about ten days |
| Vial maths | 150 IU with 1.5 ml gives 100 IU/ml, so 10 units on a U-100 barrel is 10 IU; the same vial with 3 ml gives 50 IU/ml |
Suggested Protocols
A vial of menotropin is never the whole plan. The three arrangements below are the ones the source material describes in a recovery or fertility context, and each pill opens the matching Dragon Pharma page.
What to Expect
- Spermatogenesis support. The FSH fraction acts on the Sertoli cells, and any change in that compartment is judged over weeks rather than days.
- Testosterone movement. The LH fraction can nudge total testosterone upward, and the move is clearest when the vial is run together with hCG.
- Fertility as the goal. Restoring sperm production is the purpose of the long recovery schemes, and a semen analysis, not how someone feels, is the measure.
- Division of labour. hCG drives the Leydig cells while the FSH component works on sperm output, so the two cover different tissue rather than doubling up on the same one.
- Testicular volume. Support for size after a long suppressive run is reported, and it follows the same slow timescale as the fertility effect.
- Historical caveat. Urinary menotropin has largely been displaced by recombinant gonadotropins in clinics, yet it remains the reference format that later products are compared against.
- Theoretical risk only. The chance of transmitting an infection from urine donors is assessed in the sources as purely theoretical.
Side Effects and Management
Reactions cluster around fluid balance, the injection itself and the stimulation of the ovaries in the clinical setting.
Restoration Context and Storage
This box is the page's replacement for a conventional post-cycle section, because a gonadotropin sits inside recovery rather than after it.
